BNP Paribas Arbitrage SA lifted its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 23.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,137 shares of the company’s stock after acquiring an additional 3,256 shares during the period. BNP Paribas Arbitrage SA’s holdings in Ionis Pharmaceuticals were worth $714,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Baillie Gifford & Co. raised its position in shares of Ionis Pharmaceuticals by 48.2% in the 2nd quarter. Baillie Gifford & Co. now owns 9,279,730 shares of the company’s stock valued at $386,687,000 after acquiring an additional 3,017,079 shares during the period. BB Biotech AG raised its position in shares of Ionis Pharmaceuticals by 4.7% in the 1st quarter. BB Biotech AG now owns 8,516,334 shares of the company’s stock valued at $375,400,000 after acquiring an additional 380,000 shares during the period. OppenheimerFunds Inc. raised its position in shares of Ionis Pharmaceuticals by 6.9% in the 1st quarter. OppenheimerFunds Inc. now owns 2,875,025 shares of the company’s stock valued at $126,733,000 after acquiring an additional 185,044 shares during the period. Wells Fargo & Company MN raised its position in shares of Ionis Pharmaceuticals by 3.5% in the 1st quarter. Wells Fargo & Company MN now owns 1,142,168 shares of the company’s stock valued at $50,346,000 after acquiring an additional 38,839 shares during the period. Finally, Northern Trust Corp raised its position in shares of Ionis Pharmaceuticals by 2.3% in the 1st quarter. Northern Trust Corp now owns 600,357 shares of the company’s stock valued at $26,464,000 after acquiring an additional 13,375 shares during the period. Institutional investors and hedge funds own 94.19% of the company’s stock.

Several brokerages have commented on IONS. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, April 23rd. BMO Capital Markets raised their target price on shares of Ionis Pharmaceuticals from $70.00 to $75.00 and gave the stock an “outperform” rating in a report on Monday, April 23rd. Piper Jaffray Companies began coverage on shares of Ionis Pharmaceuticals in a report on Wednesday, May 30th. They set a “hold” rating and a $50.00 target price on the stock. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 9th. Finally, Morgan Stanley dropped their target price on shares of Ionis Pharmaceuticals from $51.00 to $49.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 8th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $55.00.

In other news, Director Frederick T. Muto sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 31st. The shares were sold at an average price of $46.45, for a total transaction of $696,750.00. Following the completion of the transaction, the director now directly owns 22,127 shares of the company’s stock, valued at approximately $1,027,799.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP C Frank Bennett sold 12,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $45.00, for a total transaction of $562,500.00. Following the transaction, the senior vice president now directly owns 19,409 shares of the company’s stock, valued at $873,405. The disclosure for this sale can be found here. Insiders have sold a total of 42,656 shares of company stock valued at $1,901,087 over the last ninety days. Company insiders own 2.44% of the company’s stock.

Shares of IONS stock opened at $50.01 on Tuesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 5.33 and a current ratio of 8.38. The company has a market cap of $6.69 billion, a price-to-earnings ratio of 625.13 and a beta of 2.66. Ionis Pharmaceuticals Inc has a 52 week low of $39.07 and a 52 week high of $65.51.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Tuesday, August 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.20). The company had revenue of $117.75 million for the quarter, compared to analyst estimates of $128.22 million. Ionis Pharmaceuticals had a negative return on equity of 1.22% and a negative net margin of 7.20%. analysts forecast that Ionis Pharmaceuticals Inc will post -0.31 EPS for the current year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Featured Story: Google Finance Portfolio Workaround

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.